Companies Deepen Therapeutic Focus: The EY Firepower Report
M&A Opportunities Likely In 2020 In Cell And Gene Therapy And In Immune-Oncology.
Growth gaps and a desire to concentrate on a small number of therapeutic areas are expected to continue to drive M&A in 2020, but thought needs to be given to investing in data-driven and digital technologies, a new EY report says.
You may also be interested in...
Licensed from PharmaMar for the US market at the start of the year, Jazz Pharmaceuticals is hoping its new small-cell lung cancer therapy, Zepzelca (lurbinectedin), may have potential for other cancer types and in different combinations.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
An ultra-fast-acting allergy immunotherapy to induce tolerance to house dust mites is being sought in a collaboration between two Swiss biotechs, Anergis and Virometix.